semaglutide vs tirzepatide efficacy of versus in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial | Diabetologia Comparative safety and side effects

The injectable formulation (Ozempic) is initiated at 0.25 mg once weekly and may be titrated up to a maximum maintenance dose of 2.0 mg weekly, depending on glycemic response and tolerability

Studies in structured and preclinical models have shown that changes in this pathway can influence lipid metabolism indicators, mitochondrial activity markers, and energy balance signals under standardized conditions

Research has shown that the most common adverse effects with GLP-1s are all gastrointestinal (nausea, vomiting, and diarrhoea) and up to 19 per cent of people experienced vomiting as a result of taking the drugs in some trials

From the first semaglutide injection to ongoing maintenance, designing a therapy schedule that works for you is key to successful treatment